N-(2-fluorophenyl)pyrazine-2-carboxamide | 314055-39-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-fluorophenyl)pyrazine-2-carboxamide
• 英文别名: N-(2-fluorophenyl)-2-pyrazinecarboxamide
• CAS: 314055-39-5
• 化学式: C₁₁H₈FN₃O
• mdl: MFCD01247509
• 分子量: 217.202
• InChiKey: GTEHEVXXJAFQMD-UHFFFAOYSA-N

物化性质

• 沸点：
  263.5±30.0 °C(Predicted)
• 密度：
  1.366±0.06 g/cm3(Predicted)
• 溶解度：
  >32.6 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(2-fluorophenyl)pyrazine-2-carboxamide 在 劳森试剂 、 盐酸 、 potassium carbonate 作用下， 以 异丙醇 、 丙酮 、 甲苯 、 正丁醇 为溶剂， 生成 (1S,3r)-3-(4-(2-fluorophenyl)-5-(pyrazin-2-yl)-4H-1,2,4-triazol-3-yl)cyclobutan-1-amine dihydrochloride
  参考文献：
  名称：

  Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II

  摘要：

  DOI：

  10.1021/acs.jmedchem.1c01264
• 作为产物：
  描述：

  2-甲酸吡嗪 、 2-氟苯胺 在 吡啶 、 亚磷酸三苯酯 作用下， 反应 29.33h， 以80%的产率得到N-(2-fluorophenyl)pyrazine-2-carboxamide
  参考文献：
  名称：

  Effect of halogen bonding interaction on supramolecular assembly of halogen-substituted phenylpyrazinamides

  摘要：

  合成了一系列卤素取代的苯基吡嗪氨基酸酰胺，并进行了晶体学表征，以研究卤素键相互作用对N-苯基吡嗪-2-羧酰胺衍生物超分子组装的影响。meta-和para-碘化、溴化及氯化化合物的晶体结构中的一个显著特征是，邻近的卤素苯基和吡嗪/卤素苯基环之间有形成卤素键合成体的趋势。利用几何分析和理论计算，讨论了这些卤素键相互作用对超分子组装的影响。X⋯N卤素键距比氮和卤素原子的范德华半径之和短2.2%–7.7%。此外，理论方法显示N⋯X卤素键能量在−9.43到−23.67 kJ mol−1之间。我们的研究表明，卤素原子的选择以及在苯基吡嗪氨基酸酰胺化合物上的取代位置可能对基于卤素键的晶体设计至关重要。

  DOI：

  10.1039/c3ce40093j

文献信息

• Effect of halogen bonding interaction on supramolecular assembly of halogen-substituted phenylpyrazinamides
  作者：Hamid Reza Khavasi、Alireza Azhdari Tehrani

  DOI：10.1039/c3ce40093j

  日期：——

  A series of halogen-substituted phenylpyrazinamides have been synthesized and crystallographically characterized in order to investigate the effect of halogen bonding interaction on supramolecular assembly of N-phenylpyrazine-2-carboxamide derivatives. The notable feature in crystal structures of meta- and para-iodinated, brominated and chlorinated compounds is that there is a tendency to form a halogen bonding synthon between adjacent halophenyl and prazine/halophenyl rings. Influence of these halogen bonding interactions on supramolecular assemblies have been discussed with the help of geometrical analysis and theoretical calculations. The X⋯N halogen bonding distances are 2.2–7.7% shorter than the sum of the van der Waals radii of the nitrogen and halogen atoms. Also, theoretical methods show the N⋯X halogen bonding energies within a range of −9.43 to −23.67 kJ mol−1. Our studies show that the selection of halogen atom as well as the position of substitution on phenylpyrazinamide compound may be important for crystal design based on halogen bonding.

  合成了一系列卤素取代的苯基吡嗪氨基酸酰胺，并进行了晶体学表征，以研究卤素键相互作用对N-苯基吡嗪-2-羧酰胺衍生物超分子组装的影响。meta-和para-碘化、溴化及氯化化合物的晶体结构中的一个显著特征是，邻近的卤素苯基和吡嗪/卤素苯基环之间有形成卤素键合成体的趋势。利用几何分析和理论计算，讨论了这些卤素键相互作用对超分子组装的影响。X⋯N卤素键距比氮和卤素原子的范德华半径之和短2.2%–7.7%。此外，理论方法显示N⋯X卤素键能量在−9.43到−23.67 kJ mol−1之间。我们的研究表明，卤素原子的选择以及在苯基吡嗪氨基酸酰胺化合物上的取代位置可能对基于卤素键的晶体设计至关重要。
• 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS
  申请人：Oslo Universitetssykehus HF

  公开号：EP3810597A1

  公开（公告）日：2021-04-28
• [EN] 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE TANKYRASE
  申请人：UNIV OSLO HF

  公开号：WO2019243822A1

  公开（公告）日：2019-12-26

  The present invention relates to compounds of formula (I), tautomers, stereoisomers, pharmaceutically acceptable salts and pro-drugs thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy wherein a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, C1, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -N(R)2, and -SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, C1, Br, I), C1-6 alkyl (e.g C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); Y represents: an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); a 5- or 6-membered, saturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or a C3-6 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); and Z represents: an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -N(R)2, and -SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); or an unsaturated, 5- to 10-membered mono- or bicyclic heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, C1, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -N(R)2, and -SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl). These compounds find particular use in the treatment and/or prevention of a disease or disorder responsive to inhibition of tankyrase 1 and/or 2, for example a disorder which is mediated by tankyrase 1 and/or 2 such as cancer.
• Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II
  作者：Ruben G. G. Leenders、Shoshy Alam Brinch、Sven T. Sowa、Enya Amundsen-Isaksen、Albert Galera-Prat、Sudarshan Murthy、Sjoerd Aertssen、Johannes N. Smits、Piotr Nieczypor、Eddy Damen、Anita Wegert、Marc Nazaré、Lari Lehtiö、Jo Waaler、Stefan Krauss

  DOI：10.1021/acs.jmedchem.1c01264

  日期：2021.12.23